Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
31 slides from Jazz Pharmaceuticals's conference presentation, Jan 8, 2024
Slide 1: Innovating to Transform the Lives of Patients and Their Families
Exhibit 99.1 January 8, 2024 nd 42 Annual J.P. Morgan Healthcare Conference Innovating to Transform the Lives of Patients and Their Families Caroline ® January 2024 Rylaze patient diagnosed with ALL / LBL
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Non-GAAP Financial Measures
Transforming Lives. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non- GAAP
Slide 4: Who We Are
Our Purpose is to innovate to transform the lives of patients and their families. Who We Are We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully. William Kasen and his mom Brittan
Slide 5: Jazz in 2024: Multiple near-term growth drivers, significant pipeline catalysts
Jazz in 2024: Multiple near-term growth drivers, significant pipeline catalysts and well-positioned to deliver meaningful value CORPORATE COMMERCIAL PIPELINE DEVELOPMENT Expect double-digit Multiple near-term catalysts Well-positioned to be percentage revenue growth targeting significant market part
Slide 6: Growth & Execution
Growth & Execution Driving Growth and Delivering Value Through Continued Execution 6 January 2024
Slide 7: Consistent Growth Driving Long-Term Shareholder Value
GROWTH & EXECUTION PIPELINE COMMERCIAL Consistent Growth Driving Long-Term Shareholder Value Expect to meet 2023 total, neuroscience and $3.75 – 1 oncology revenue guidance 1 $3.875 $3.7 19 Consecutive Years $3.1 YoY Revenue Growth 2005 – 2023G $2.4 $2.2 $1.9 15% Total Revenue CAGR 2 2018 – 2023G mi
Slide 8: Durable and Growing Commercial Portfolio
GROWTH & EXECUTION PIPELINE COMMERCIAL Durable and Growing Commercial Portfolio 1 3 2018 Revenue 2023 Revenue Guidance Vision 2025 $1.9 billion $3.75 - $3.875 billion $5 billion + Xyrem & AG royalties + Xyrem & AG royalties Xyrem 60% 26% 26% 49% 2 of revenues driven Vision 2025: by oncology + Epidio
Slide 9: Durable and Growing Commercial Portfolio: Vision 2025
GROWTH & EXECUTION PIPELINE COMMERCIAL Durable and Growing Commercial Portfolio 1 Vision 2025 Growth to Vision 2025 2018 Revenue $5 billion $1.9 billion >$3B Expected Top-Line Revenue Growth + Xyrem & AG royalties Since 2018 Xyrem 60% +34% 26% 26% 3 Expected Increase in Non-Sleep Revenue Share Since
Slide 10: Strong Track Record of Corporate Development Success
GROWTH & EXECUTION PIPELINE COMMERCIAL Strong Track Record of Corporate Development Success WELL-POSITIONED TO BE A PARTNER OF CHOICE Orphan Medical EUSA Celator GW Pharma Acquisition Acquisition Acquisition Acquisition Established Jazz’s Expanded oncology footprint, Strengthened Transformative tran
Slide 11: Vision 2025 is Built on Our Core Strengths
GROWTH & EXECUTION PIPELINE COMMERCIAL Vision 2025 is Built on Our Core Strengths OPERATIONAL COMMERCIAL PIPELINE EXCELLENCE Executing successful launches Ability to invest meaningfully in R&D Disciplined capital allocation #1 treatment in narcolepsy Expanded R&D capabilities Already achieved operat
Slide 12: Pipeline
Pipeline Multiple Near-term Catalysts Targeting Significant Market Opportunities 12 January 2024
Slide 13: Robust and Productive Pipeline for Sustainable Growth
GROWTH & EXECUTION PIPELINE COMMERCIAL Robust and Productive Pipeline for Sustainable Growth PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 2 JZP815 Zanidatamab 2 Undisclosed targets Zanidatamab Pan-Raf Inhibitor Program HER2-targeted bispecific antibody 1 Ras/Raf/MAP kinase pathway HER2-targeted bispecific a
Slide 14: Multiple Pipeline Catalysts Through 2025
GROWTH & EXECUTION PIPELINE COMMERCIAL Multiple Pipeline Catalysts Through 2025 PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY NEAR-TERM CATALYSTS Key Clinical Programs 2L BTC (pivotal) Complete BLA Submission expected 1H24 Phase 3 1L GEA (pivotal) Phase 3 Top-line PFS Readout – targeting late 2024 Za
Slide 15: Zanidatamab: Recent Data De-Risks $2B+ Potential Opportunity
GROWTH & EXECUTION PIPELINE COMMERCIAL Zanidatamab: Recent Data De-Risks $2B+ Potential Opportunity Announced MD Anderson Collaboration Meaningful data generation and rapid progression 15 months post-transaction Dec 2023 BTC Data Presented at ASCO Nov 2023 Monotherapy Activity Oct 2023 Transaction A
Slide 16: Zanidatamab: Recent Data De-Risks $2B+ Potential Opportunity
GROWTH & EXECUTION PIPELINE COMMERCIAL Zanidatamab: Recent Data De-Risks $2B+ Potential Opportunity Announced MD Anderson Collaboration Studying zanidatamab as monotherapy and in combination in: • Early-stage BC • Cancers where other HER2-targeted therapies failed Meaningful data generation and rapi
Slide 17: Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential
GROWTH & EXECUTION PIPELINE COMMERCIAL Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential • Increased HERIZON-GEA-01 enrollment from 714 to 918 to improve statistical power for OS analysis while maintaining late 2024 PFS top-line readout target based on original enrollment • Maint
Slide 18: Zepzelca: Opportunity to Address Unmet Need as Front-Line Therapy
GROWTH & EXECUTION PIPELINE COMMERCIAL Zepzelca: Opportunity to Address Unmet Need as Front-Line Therapy 4 Well-established as 2L SCLC treatment of choice, generating over $820 million in revenue since launch 2 KEY CATALYST SCLC U.S. Patients LS SCLC • Expect Phase 3 top-line PFS readout in ES 1L SC
Slide 19: Suvecaltamide: Near-Term Essential Tremor Data Readout
GROWTH & EXECUTION PIPELINE COMMERCIAL Suvecaltamide: Near-Term Essential Tremor Data Readout KEY CATALYST Without • Expect top-line data from Phase 2b Essential Tremor (ET) trial late 1H24 tremor SIGNIFICANT UNMET NEED 1-3 • High unmet need: no newly approved ET pharmacotherapy in >50 years 4,5 • I
Slide 20: Novel Early Programs Continue to Advance
GROWTH & EXECUTION PIPELINE COMMERCIAL Novel Early Programs Continue to Advance 1 2 JZP815 JZP898 • Highly selective and potent inhibitor of activity against all RAF • Designed to be first in-class, systemically delivered, conditionally protomers activated IFNα molecule for treatment of a wide varie
Slide 21: Commercial
Commercial Growing and Diverse Revenue Streams 21 January 2024
Slide 22: Key Growth Drivers Contributing to Top-Line Revenues
GROWTH & EXECUTION PIPELINE COMMERCIAL Key Growth Drivers Contributing to Top-Line Revenues $3,750 – 1 $3,875 Consecutive Years GROWING & INCREASINGLY DIVERSIFIED PORTFOLIO of Revenue Growth 2 1 • 2020 – 2023G revenues expected to grow by >60% 2005 – 2023G 1 2 • Oncology revenues expected to be ~27%
Slide 23: Rely on Rylaze: Successful Launch and Strong Demand
GROWTH & EXECUTION PIPELINE COMMERCIAL Rely on Rylaze: Successful Launch and Strong Demand KEY HIGHLIGHTS Sustained asparaginase activity over the course of therapy essential to treatment 1 success of ALL/LBL patients 2 • $660 million in revenue since launch in mid-2021 GROWTH OPPORTUNITIES • Contin
Slide 24: Epidiolex: High Unmet Need in Pediatric Onset Epilepsy
GROWTH & EXECUTION PIPELINE COMMERCIAL Epidiolex: High Unmet Need in Pediatric Onset Epilepsy KEY HIGHLIGHTS Broad spectrum efficacy through novel mechanism of action 1 • $1.8 billion in revenue since acquisition mid-2021 GROWTH OPPORTUNITIES 2 • Further data generation, including potential beyond-s
Slide 25: Xywav: Success Reinforces Durability in Sleep
GROWTH & EXECUTION PIPELINE COMMERCIAL Xywav: Success Reinforces Durability in Sleep KEY HIGHLIGHTS 1 • Annualizing at $1.3B , as of 3Q23 • First and only FDA-approved therapy to treat IH • Received Orphan Drug Exclusivity in IH • Approved to treat the full condition of IH, including sleep inertia,
Slide 26: Near-Term Catalysts to Drive Substantial Value Creation
COMMERCIAL Near-Term Catalysts to Drive Substantial Value Creation COMMERCIAL CATALYSTS PIPELINE CATALYSTS 2024 / 2025 Epidiolex / Epidyolex Zanidatamab • Additional ex-U.S. launches and indication • Complete BLA submission in BTC expected 1H24 expansion expected through 2024 Commercial catalysts dr
Slide 27: Thank You
Thank You o~ Pharmaceuticals.
Slide 28: Appendix
Appendix o~ Pharmaceuticals.
Slide 29: GAAP and Non-GAAP Adjusted Operating Margin – Year Ended December 31, 2021
1 GAAP and Non-GAAP Adjusted Operating Margin – Year Ended December 31, 2021 The following table provides a reconciliation of the Company’s GAAP reported cost of product sales, SG&A expenses and R&D expenses to non-GAAP adjusted cost of products sales, SG&A expenses and R&D expenses and the calculat
Slide 30: GAAP and Non-GAAP Adjusted Operating Margin – Year Ended December 31, 2022
1 GAAP and Non-GAAP Adjusted Operating Margin – Year Ended December 31, 2022 The following table provides a reconciliation of the Company’s GAAP reported cost of product sales, SG&A expenses and R&D expenses to non-GAAP adjusted cost of products sales, SG&A expenses and R&D expenses and the calculat
Slide 31: GAAP and Non-GAAP Adjusted Operating Margin – FY 2023 Guidance
1,2 GAAP and Non-GAAP Adjusted Operating Margin – FY 2023 Guidance The following table provides a reconciliation of the Company’s projected 2023 GAAP cost of product sales, SG&A expenses and R&D expenses to non-GAAP adjusted cost of products sales, 1 SG&A expenses and R&D expenses, in each case base
Jazz Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix